TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma

18 Jun 2021 07:35:04 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress

11 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma

09 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting

04 Jun 2021 09:00:00 By Nasdaq GlobeNewswire

TG Therapeutics to Present at Upcoming Investor Conferences

27 May 2021 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

25 May 2021 07:00:01 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings

13 May 2021 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

10 May 2021 07:00:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the B. Riley Securities Neuroscience Conference

26 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab

26 Apr 2021 07:00:01 By Nasdaq GlobeNewswire

TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and Venetoclax

21 Apr 2021 07:00:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting

16 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis

15 Apr 2021 16:00:00 By Nasdaq GlobeNewswire

TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia

29 Mar 2021 07:42:09 By Nasdaq GlobeNewswire

TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journal of Clinical Oncology

09 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting

04 Mar 2021 16:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

04 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results

02 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update

26 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology

23 Feb 2021 07:30:00 By Nasdaq GlobeNewswire